Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

GSK starts large African study of injectable drug to prevent HIV

Written by: | no-reply@reuters.com | Dated: Thursday, November 30th, 2017

 

GSK starts big African study of injectable drug to prevent HIV

 

(Reuters) – ViiV Healthcare, GlaxoSmithKline Plc’s HIV unit, said on Thursday it started an African study to evaluate long-acting injectable drug for the prevention of HIV infection in sexually active women.

The cabotegravir study seeks to enrol 3,200 women aged 18 to 45 years from sub-Saharan African countries, ViiV Healthcare said in a statement.

The HPTN 084 Phase III study will evaluate injections given every two months, ViiV Healthcare said.

The study is being conducted through a public-private funding by ViiV Healthcare, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Bill & Melinda Gates Foundation, the company said.

Viiv Healthcare in 2016 had started a large study on HIV-uninfected men and transgender women who have sex with men to test an experimental long-acting injection for preventing the virus that causes AIDS.

 

Reporting by Subrat Patnaik in Bengaluru; Editing by Akshay Lodaya

 

Reuters source:

https://www.reuters.com/article/us-gsk-hiv-prevention/gsk-starts-big-african-study-of-injectable-drug-to-prevent-hiv-idUSKBN1DU0TA

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review

Subscribe

Ad Right Bottom

Main Navigation